Asset Details
Do you wish to reserve the book?
Tumor-infiltrating NY-ESO-1-specific CD8⁺ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Tumor-infiltrating NY-ESO-1-specific CD8⁺ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer
Do you wish to request the book?
Tumor-infiltrating NY-ESO-1-specific CD8⁺ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Tumor-infiltrating NY-ESO-1-specific CD8⁺ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer
2010
Overview
NY-ESO-1 is a \"cancer-testis\" antigen frequently expressed in epithelial ovarian cancer (EOC) and is among the most immunogenic tumor antigens defined to date. In an effort to understand in vivo tolerance mechanisms, we assessed the phenotype and function of NY-ESO-1-specific CD8⁺ T cells derived from peripheral blood lymphocytes (PBLs), tumor-infiltrating lymphocytes (TILs), and tumor-associated lymphocytes (TALs) of EOC patients with NY-ESO-1-expressing tumors, with or without humoral immunity to NY-ESO-1. Whereas NY-ESO-1-specific CD8⁺ T cells were readily detectable ex vivo with tetramers in TILs and TALs of seropositive patients, they were only detectable in PBLs following in vitro stimulation. Compared with PBLs, tumor-derived NY-ESO-1-specific CD8⁺ T cells demonstrated impaired effector function, preferential usage of dominant T-cell receptor, and enriched coexpression of inhibitory molecules LAG-3 and PD-1. Expression of LAG-3 and PD-1 on CD8⁺ T cells was up-regulated by IL-10, IL-6 (cytokines found in tumor ascites), and tumor-derived antigen-presenting cells. Functionally, CD8⁺LAG-3⁺PD-1⁺ T cells were more impaired in IFN-γ/TNF-α production compared with LAG-3⁺PD-1⁻ or LAG-3⁻PD-1⁻ subsets. Dual blockade of LAG-3 and PD-1 during T-cell priming efficiently augmented proliferation and cytokine production by NY-ESO-1-specific CD8⁺ T cells, indicating that antitumor function of NY-ESO-1-specific CD8⁺ T cells could potentially be improved by therapeutic targeting of these inhibitory receptors.
Publisher
National Academy of Sciences,National Acad Sciences
Subject
/ Antibodies, Monoclonal - pharmacology
/ Antigens
/ Antigens, Neoplasm - immunology
/ Antigens, Neoplasm - metabolism
/ Apoptosis Regulatory Proteins - metabolism
/ Ascites
/ CD8-Positive T-Lymphocytes - immunology
/ CD8-Positive T-Lymphocytes - metabolism
/ Cells
/ Enzyme-Linked Immunosorbent Assay
/ Female
/ Gene Expression Regulation, Neoplastic - immunology
/ Humans
/ Lymphocytes, Tumor-Infiltrating - immunology
/ Lymphocytes, Tumor-Infiltrating - metabolism
/ Membrane Proteins - immunology
/ Membrane Proteins - metabolism
/ Ovarian Neoplasms - immunology
/ patients
/ Programmed Cell Death 1 Receptor
/ Signal Transduction - drug effects
/ Signal Transduction - immunology
/ Tumors
